文献速递精神分裂症与精神病性障碍

精神分裂症不同亚组患者对抗精神病药物的反应:系统综述与荟萃分析

The response of subgroups of patients with schizophrenia to different antipsychotic drugs: a systematic review and meta-analysis.
PubMed 文献 · Lancet Psychiatry · 2022-10-10

在507项随机效应亚组检验中,46项(9%)显示亚组间差异显著,但无明确证据提示特定亚组应选用何种药物。作者认为各亚组药物效应通常与一般人群相似,但亚组证据尤其副作用证据较少,建议证据不足时参考一般人群研究结果。

要点

  • 各亚组抗精神病药物效应通常与一般人群相似,仅9%亚组检验显示显著差异。
  • 亚组研究数量有限,尤其副作用相关证据较少。
  • 亚组证据不足时,指南制定者和临床医生可考虑参考一般人群研究结果。

核心结论

  • 抗精神病药物在不同患者亚组中的效应通常与精神分裂症一般人群相似。
  • 亚组间显著的疗效差异较少(507项检验中46项,9%),且无明确证据指导特定亚组的药物选择。
  • 亚组证据尤其副作用证据有限,证据不足时可参考一般人群研究结果。

研究设计与样本

  • 系统综述与荟萃分析,检索既往系统综述参考文献、Cochrane精神分裂症组研究注册库(建库至2020年4月27日)和PubMed(2020年4月1日至2021年6月14日)。
  • 纳入单盲或更高质量随机对照试验,评估16种第二代和18种第一代抗精神病药物,对象为精神分裂症一般人群或指定亚组。
  • 排除稳定期精神分裂症(复发预防)研究、高偏倚风险研究及因分配和盲法质量担忧的中国大陆研究。
  • 412项试验纳入一般人群,42项难治性精神分裂症,25项儿童青少年,20项首发,20项以阴性症状为主,13项共病物质使用,11项老年患者。

主要发现

  • 各亚组抗精神病药物效应通常与一般人群相似。
  • 亚组研究数量有限,尤其副作用相关证据较少。

关键数值与推荐

  • 亚组构成:一般人群412项、难治性42项、儿童青少年25项、首发20项、阴性症状为主20项、共病物质使用13项、老年11项。

临床怎么用

  • 临床医生可参考一般人群的抗精神病药物证据用于亚组患者,尤其当亚组证据不足时。
  • 指南制定者应考虑在亚组证据有限时使用一般人群研究结果。
  • 对亚组患者选择药物时需注意副作用证据尤其有限。

局限性

  • 亚组研究数量有限,尤其副作用相关证据较少。
  • 排除中国大陆研究可能限制证据代表性。
  • 未提供 ethnicity 数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: As comparatively few trials in subgroups of patients with schizophrenia have been done, clinicians need to know whether they can rely on the results of randomised controlled trials (RCTs) in the general population of patients with schizophrenia. We aimed to compare the efficacy and side-effects of antipsychotic drugs in different subgroups. METHODS: In this systematic review and meta-analysis, we searched reference lists of previous systematic reviews and meta-analyses, the Cochrane Schizophrenia Group's Study-Based Register (from database inception to April 27, 2020), and PubMed (from April 1, 2020 to June 14, 2021). We excluded studies in patients with stable schizophrenia (ie, relapse prevention studies), studies with a high risk of bias, and studies from mainland China due to quality concerns concerning allocation and masking methods. We included single-blind RCTs or better that assessed one or more of 16 second-generation and 18 first-generation antipsychotics in the general population of patients with schizophrenia or in one or more of the subgroups: children and adolescents (age range as defined in the original studies), patients with a first episode, patients with predominant or prominent negative symptoms, patients with comorbid substance use, patients with treatment-resistant schizophrenia, or older patients (age range as defined in the original studies). Two authors independently screened the results of the search, retrieved full-text articles, and checked the inclusion criteria. Using the Preferred Reporting Items for Systematic Reviews and Meta-analyses guideline, all parameters were extracted in duplicate. The primary outcome was change in overall symptoms. We compared drug efficacy between subgroups, by sex, schizoaffective disorder versus schizophrenia, and study origin using random-effects, inverse variance meta-analyses and random-effects subgroup tests, and meta-regression. FINDINGS: We included 537 RCTs with 76 382 participants, 26 627 (34·9%) women, 49 755 (65·1%) men, mean age 37·3 years (range of means 7·9-80·2; ethnicity data not available). 412 RCTs included patients in the general population of patients with schizophrenia, 42 included patients with treatment-resistant schizophrenia, 25 included children and adolescents, 20 included patients with their first episode, 20 included patients with predominant or prominent negative symptoms, 13 included patients with comorbid substance use, and 11 included older patients. Of 507 random-effects subgroup tests done, 46 (9%) showed a significant difference (p<0·05) between subgroups, but there was no clear indication as to which drug should be used in which subgroup. INTERPRETATION: The effects of antipsychotics in various patient subgroups were usually similar to those in the general population of patients with schizophrenia, but comparably few studies contributed to the subgroups, in particular in terms of side-effects. If the evidence for treatment in a given subgroup is small, guideline makers and clinicians should consider using the results in the much better studied group of the general population of patients with schizophrenia. FUNDING: German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung; FKZ 01KG1508).

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Leucht S, Chaimani A, Krause M, et al. The response of subgroups of patients with schizophrenia to different antipsychotic drugs: a systematic review and meta-analysis. Lancet Psychiatry. 2022. PMID: 36228647. doi:10.1016/S2215-0366(22)00304-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。